CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Highlights Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 21:00:02 20/01/2026 GMT			5-day change	1st Jan Change
218.19 ^USD	-0.69%		-0.37%	+9.38%

04:21pm	Jefferies Adjusts Price Target on Charles River Laboratories International to $255 From $205, Maintains Buy Rating	MT
01:21pm	Greenland, Tariffs, and the Quiet Revolt of the Bond Market

Highlights

01:21pm	Greenland, Tariffs, and the Quiet Revolt of the Bond Market
01-13	Charles River Laboratories International Seeks Acquisitions	CI
01-12	Charles River Laboratories Reports Two Planned Acquisitions; Names Namandje Bumpus as Chief Scientific and Innovation Officer	MT
01-12	Charles River to buy Cambodia-based monkey supplier for $510 million	RE
01-12	Charles River Laboratories provides business updates	RE
01-11	Charles River Laboratories International, Inc. exercised its option to acquire remaining 79% stake in PathoQuest SAS for ?51.6 million.	CI
01-11	Charles River Laboratories International, Inc. entered into agreement to acquire Assets of K.F. Ltd. from K.F. Ltd. for $510 million.	CI
01-11	Charles River Laboratories International, Inc. entered into agreement to acquire Assets of K.F. Ltd. from K.F. Ltd. for $510 million.	CI
01-08	Charles River Laboratories International, Inc. Announces Chief Executive Officer Changes	CI
01-08	Charles River Laboratories International, Inc. Announces Changes in Board	CI
12-03	Charles River Laboratories International Inc - DSA Net Book-to-Bill Improved Each Month Since Q3 2025 - SEC Filing	RE
11-06	The Market Can't Make Up Its Mind
11-05	Charles River Laboratories International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 27, 2025	CI
11-05	Charles River Laboratories International, Inc. Revises Earnings Guidance for the Year 2025	CI
11-05	Charles River Laboratories International, Inc. announces an Equity Buyback for $1,000 million worth of its shares.	CI
11-05	Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on August 7, 2024.	CI
11-05	Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on August 7, 2024.	CI
11-05	Charles River Laboratories International, Inc. Provides Earnings Guidance for the Fourth Quarter of 2025	CI
11-05	Charles River plans to sell underperforming assets, ramp up cost cutting	RE
11-05	Charles River Laboratories Fiscal Q3 Non-GAAP Earnings, Revenue Drop; Fiscal 2025 Guidance Updated	MT
11-05	Charles River raises annual profit forecast on stabilizing biotech demand	RE
11-05	Earnings Flash (CRL) Charles River Laboratories International, Inc. Posts Q3 Adjusted EPS $2.43, vs. FactSet Est of $2.34	MT
11-05	Earnings Flash (CRL) Charles River Laboratories International, Inc. Reports Q3 Revenue $1.00B, vs. FactSet Est of $990.8M	MT
11-05	Charles River Laboratories Q3 revenue beats estimates	RE
28/10/25	Charles River Laboratories International, Inc. authorizes a Buyback Plan.	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Biotechnology & Medical Research

Highlights

Filters